Oral Epitalon for prolonged stress and Vilon during recovery from infection: two placebo comparisons
Randomized study in people · 2021
- What was studied
- Epimental: 560 adults aged 35–68 after prolonged occupational or emotional stress, including time-zone changes (270 active, 290 placebo). Regevil: 520 adults aged 43–76 recovering from acute respiratory, bacterial or viral illness (276 active, 244 placebo).
- Main finding
- After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.
Related evidence maps: Military & occupational ↗
Reported findings and study design
Reported findings
Two reported randomized comparisons under separate ethics protocols in 2018. Epimental assessments included symptoms, serum melatonin at 09:00 and 21:00, plasma cortisol and ACTH. Regevil assessments included symptoms, immunofluorescence lymphocyte phenotyping, immunoglobulins and a lymphocyte migration assay.
Population or model Epimental: 560 adults aged 35–68 after prolonged occupational or emotional stress, including time-zone changes (270 active, 290 placebo). Regevil: 520 adults aged 43–76 recovering from acute respiratory, bacterial or viral illness (276 active, 244 placebo).
Dose, route and schedule
St. Petersburg Institute of Bioregulation and Gerontology ethics protocol No. 7, 5 March 2018 (Epimental). St. Petersburg Institute of Bioregulation and Gerontology ethics protocol No. 2, 24 January 2018 (Regevil). Each comparison used one oral capsule daily with a meal for 20 days, with placebo on the same schedule. Neither the 2021 paper nor the 2022 companion gives peptide mass per capsule or identifies the study batch. The standalone approved protocols have not been located in the public sources reviewed.
Protocol source ↗ · 2022 companion publication, pp. 99–104, methods and repeated results
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Epimental · sleep disturbance | 87/270 vs 211/290 reporting disturbed sleep after treatment | Epimental vs placebo. At baseline: 182/270 vs 195/290. · Table 1 marks p<0.05 vs placebo and vs baseline. |
| Epimental · 21:00 serum melatonin | 35.1 → 72.3 vs 31.4 → 37.2 pg/mL | Epimental vs placebo, baseline to day 20. · Table 2 marks p<0.05 for both comparisons. |
| Regevil · fatigue | 110/276 vs 200/244 reporting fatigue after treatment | Regevil vs placebo. At baseline: 263/276 vs 220/244. · Table 5 marks p<0.05 vs placebo and vs baseline. |
| Regevil · CD3+ lymphocytes | 52.4% → 61.6% vs 48.3% → 50.3% | Regevil vs placebo, baseline to day 20. · Table 4 marks p<0.05 within the Regevil group only. |
Protocol and formulation records
| Preparation | Documentary lead | What it establishes |
|---|---|---|
| Epimental (AEDG) | St. Petersburg Institute of Bioregulation and Gerontology ethics protocol No. 7, 5 March 2018 (Epimental). | The 2022 paper also cites Italian supplement notification 115680 for EPITALON. It gives no link between a specified capsule strength and the 2018 study batch. |
| Regevil (KE) | St. Petersburg Institute of Bioregulation and Gerontology ethics protocol No. 2, 24 January 2018 (Regevil). | The 2022 paper cites free-sale certificate CVL-SA/811/2021/511 for Vilon. That later product reference supplies no strength for the capsules administered in the trial. |
The ethics identifiers come from the two published accounts. The product identifiers are reported by the 2022 authors. Neither report reproduces a signed protocol or a label for the trial lot.
Epimental · people reporting each symptom
| Symptom | Epimental, before → after (n=270) | Placebo, before → after (n=290) |
|---|---|---|
| Disturbed sleep | 182 → 87 | 195 → 211 |
| Fatigue | 268 → 110 | 286 → 284 |
| Reduced work capacity | 267 → 107 | 280 → 271 |
| Apathy | 259 → 135 | 275 → 262 |
| Emotional lability | 265 → 100 | 282 → 288 |
| Poor concentration | 175 → 88 | 199 → 202 |
Table 1, p. 29. Counts are printed numerators. The reported 97.3% for 284/290 is arithmetically inconsistent. The table marks every Epimental follow-up value p<0.05 against baseline and placebo.
Epimental · blood hormone measurements
| Hormone | Epimental, before → after | Placebo, before → after |
|---|---|---|
| Melatonin at 09:00 (pg/mL) | 6.9 ± 1.1 → 18.2 ± 1.4 | 6.3 ± 0.9 → 7.8 ± 1.1 |
| Melatonin at 21:00 (pg/mL) | 35.1 ± 1.3 → 72.3 ± 3.6 | 31.4 ± 1.2 → 37.2 ± 1.9 |
| Cortisol (nmol/L) | 239.1 ± 18.9 → 386.7 ± 18.4 | 232.7 ± 20.1 → 236.4 ± 19.6 |
| ACTH (pg/mL) | 12.6 ± 1.0 → 31.4 ± 1.0 | 10.9 ± 0.9 → 11.2 ± 1.0 |
Tables 2–3, p. 29. Values retain the printed ± terms. All four Epimental follow-up values carry both significance markers (p<0.05). Two sampling times cannot characterize a full circadian rhythm.
Regevil · people reporting each symptom
| Symptom | Regevil, before → after (n=276) | Placebo, before → after (n=244) |
|---|---|---|
| Fatigue | 263 → 110 | 220 → 200 |
| General weakness | 270 → 133 | 239 → 222 |
| Reduced work capacity | 247 → 107 | 216 → 193 |
| Poor concentration | 155 → 88 | 119 → 115 |
Table 5, p. 32. The authors mark all four follow-up comparisons p<0.05 against baseline and placebo.
Regevil · selected immune measurements
| Measure | Regevil, before → after | Placebo, before → after |
|---|---|---|
| Leukocytes (×10⁹/L) | 4.6 → 6.5 | 4.3 → 4.8 |
| CD3+ (%) | 52.4 → 61.6 | 48.3 → 50.3 |
| CD4+ (%) | 27.4 → 33.2 | 23.7 → 25.7 |
| CD8+ (%) | 32.1 → 27.3 | 29.1 → 30.4 |
| CD20+ (%) | 13.9 → 15.0 | 14.1 → 14.2 |
| CD4+/CD8+ ratio | 0.90 → 1.20 | 0.80 → 0.80 |
| Lymphocyte migration assay (%) | 84.2 → 76.1 | 89.4 → 86.6 |
Table 4, p. 31. Among these rows, leukocytes, CD3+, CD4+ and the migration assay carry a within-Regevil significance marker. The table gives no between-group significance test. CD8+, CD20+ and the ratio have no marker.
Trofimova and colleagues’ 2022 English mini-review repeats both 2021 comparisons. Each protocol date and number, all four arm sizes, and the follow-up sleep and fatigue counts match. It contributes no additional cohort. Whether any individual took part in both protocols or another occupational program remains unknown. The authors reported no adverse effects during either course. The short observation window limits safety conclusions. The Epimental exposure categories (142 with jet lag and 430 with occupational stress) exceed the group total of 560 when added. If both exposure counts are accurate, at least 12 participants fall in both categories. The exact intersection is unreported. The paper reports neither objective sleep duration nor subsequent infection rates.
Source for these results ↗ · Reviewed 2026-11-18
Study limitations and source details
Study limitations
- The authors describe random assignment but give no sequence-generation, concealment or masking details. Symptoms were self-reported. Follow-up beyond the course and systematic adverse-event ascertainment are unspecified.
- Occupational program totals in the introduction come from earlier sources. The two protocols have different entry criteria and comparators. The 2022 report reproduces both comparisons. Recruitment records linking individual participants to other studies are unavailable.
Source details
Journal report of two placebo comparisons
Publisher PDF, pp. 27–33. Epimental methods and Tables 1–3 on pp. 28–29. Regevil methods and Tables 4–5 on pp. 30–32.
Sources checked
Added to the library
Citation
Author affiliations · Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Biomedical Agency, Moscow · St. Petersburg Institute of Bioregulation and Gerontology
S. V. Trofimova, A. V. Trofimov, O. M. Ivko. Oral Epitalon for prolonged stress and Vilon during recovery from infection: two placebo comparisons Ways to increase the body’s reserve capacities in individuals under the influence of unfavorable productive and climatoecological factors. Vrach. 2021;32(3):27–33.
Study source ↗ · DOI 10.29296/25877305-2021-03-05 · Bibliography entry · Link to this summary
Related compounds
Epitalon
A synthetic tetrapeptide, Ala–Glu–Asp–Gly (AEDG, also called Epithalon), developed from pineal-gland research. Human studies examined melatonin secretion, circadian markers and retinal function.
Vilon
A synthetic two-amino-acid peptide (Lys–Glu, or KE) studied in thymus, immune and tissue-repair research.